| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5586674 | Best Practice & Research Clinical Endocrinology & Metabolism | 2016 | 13 Pages |
Abstract
The evidence base for treatments in monogenic and young-onset type 2 diabetes relies on studies of moderate quality at best and largely on extrapolation from work conducted in older type 2 diabetes subjects. Better quality, larger studies, particularly of newer agents would improve treatment prospects for young adults with diabetes.
Keywords
SGLT-2TNDMPNDMHNF4Ahepatocyte nuclear factor 1 alphaPermanent neonatal diabetesHNF1BMELASHNF1AT1DMT2DMGCKUnited StatesLatent Autoimmune Diabetes in AdultsMaturity-onset diabetes of the youngMonogenic diabetesneonatal diabetestype 1 diabetes mellitusType 2 diabetes mellitusMaternally inherited diabetes and deafnesshepatocyte nuclear factor 4 alphaLADAMODYMiddC-reactive proteinCRPPersonalised medicineGlucokinase
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Endocrinology
Authors
Katharine R. (Associate Professor of Diabetes),